Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Arcus Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Arcus Biosciences wird ein jährliches Gewinn- und Umsatzwachstum von 15% bzw. 21.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -213.7% betragen.

Wichtige Informationen

6.9%

Wachstumsrate der Gewinne

13.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.0%
Wachstumsrate der Einnahmen	10.6%
Zukünftige Eigenkapitalrendite	-166.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	24 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

May 12

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

Jan 07

Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically

Nov 25

Analysts Just Shaved Their Arcus Biosciences, Inc. (NYSE:RCUS) Forecasts Dramatically

Aug 08

Gewinn- und Umsatzwachstumsprognosen

NYSE:RCUS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	266	-382	-176	-95	6
12/31/2025	180	-409	-329	-342	9
12/31/2024	274	-316	-243	-367	7
3/31/2024	237	-231	-235	-210	N/A
12/31/2023	117	-307	-330	-306	N/A
9/30/2023	120	-293	-306	-288	N/A
6/30/2023	121	-287	-316	-306	N/A
3/31/2023	119	-279	-326	-314	N/A
12/31/2022	112	-267	426	438	N/A
9/30/2022	433	80	426	446	N/A
6/30/2022	409	67	447	473	N/A
3/31/2022	392	58	439	464	N/A
12/31/2021	383	53	-282	-256	N/A
9/30/2021	38	-278	-263	-244	N/A
6/30/2021	93	-199	14	26	N/A
3/31/2021	85	-168	70	76	N/A
12/31/2020	78	-123	108	111	N/A
9/30/2020	78	-88	150	152	N/A
6/30/2020	15	-112	-93	-92	N/A
3/31/2020	15	-95	-89	-88	N/A
12/31/2019	15	-85	-75	-73	N/A
9/30/2019	7	-80	-73	-71	N/A
6/30/2019	9	-69	-58	-55	N/A
3/31/2019	9	-54	-50	-47	N/A
12/31/2018	8	-50	-47	-43	N/A
9/30/2018	8	-51	-24	-20	N/A
6/30/2018	4	-63	-36	-33	N/A
3/31/2018	3	-59	-33	-29	N/A
12/31/2017	1	-53	N/A	-25	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RCUS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RCUS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RCUS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RCUSDie Einnahmen des Unternehmens (21.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8% pro Jahr).

Hohe Wachstumseinnahmen: RCUSDie Einnahmen des Unternehmens (12.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RCUS wird voraussichtlich in 3 Jahren unrentabel sein.

Arcus Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 52%

Consensus revenue estimates increase by 35%, EPS downgraded

Price target decreased by 7.9% to US$39.70

Price target decreased to US$50.10

Price target decreased to US$50.80

Consensus revenue estimates fall by 18%

Recent updates

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

Consensus revenue estimates increase by 52%

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$241k worth of stock

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Chief Operating Officer notifies of intention to sell stock

Consensus revenue estimates increase by 35%, EPS downgraded

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Price target decreased by 7.9% to US$39.70

Arcus Biosciences, Inc. Announces Data from A Phase 1B Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer

Co-Founder notifies of intention to sell stock

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Co-Founder notifies of intention to sell stock

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Arcus Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Insufficient new directors

COO & Director notifies of intention to sell stock

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcus Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New minor risk - Shareholder dilution

Arcus Biosciences, Inc. announced that it expects to receive $19.4526 million in funding from Gilead Sciences, Inc.

COO & Director notifies of intention to sell stock

COO & Director recently sold US$243k worth of stock

COO & Director notifies of intention to sell stock

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Arcus Biosciences, Inc. Provides Updated Results from an Interim Analysis of ARC-7

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

COO & Director recently sold US$147k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

COO & Director notifies of intention to sell stock

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

COO & Director recently sold US$507k worth of stock

Investor sentiment improved over the past week

Arcus Biosciences, Inc. Announces Positive Update from the Fourth Interim Analysis of ARC-7

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Arcus Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022

COO & Director recently sold US$333k worth of stock

Price target decreased to US$50.10

Arcus Biosciences, Inc. Appoints Dimitry S.A. Nuyten as Chief Medical Officer

Price target decreased to US$50.80

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Arcus Biosciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

COO & Director recently sold US$272k worth of stock

Investor sentiment improved over the past week

Consensus revenue estimates fall by 18%

Price target decreased to US$59.70

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers